Skip to main content

Late breaking study on Voclosporin to be presented in Madrid

More good news.

Here's the title the session with  late breaking news to be presented in Madrid on Sunday June 4th.

"Steroid-sparing efficacy of voclosporin in active lupus nephritis: stable kidney function and BP without electrolyte complications at 48 weeks James Tumlin, Chattanooga, U.S.A."

 The source is the program for the "54th ERA-EDTA Conference, Madrid Spain:

See: ERA-EDTA Conference Program p. 78

More to follow, and please tell us what you know about any prior research on this topic.

Kind regards to all,

TC

ps Thanks to Lunacy for first spotting this news!  

Comments

  1. Lunacy aka John GaltMay 29, 2017 at 7:54 AM

    Happy to see Auph's story continued to be shared as they continue to get more trial sites up and running.

    ReplyDelete
    Replies
    1. vidpok45May 29, 2017 at 8:08 AM

      The fact that Voclosporin is both more effective than the current treatment and allows for the reduction in the use of oral steroids is a stunning achievement not to be underestimated. This will lessen the onset of diabetes, along with reducing the many other complications which are associated with the use of high dose steroids. The approval of Voclosporin will be the ultimate achievement for Glickman who has dedicated his life to finding an answer for LN, and now that answer is here.

      Delete

Post a Comment

Popular posts from this blog

iHub has been hijacked by trolls

Yup. iHub can't get rid of "Biotech Researcher," aka BR.  It's both a win for BR (the troll), and a huge loss for iHub. Their platform loses value and credibility when they refuse to take action on perma-trolls that derail the discussion and distract investors from their efforts to just honestly share information and opinions on the equities they own. So shame on iHub for not taking action to resolve this. I'm going to cease and desist on posting there until the troll (BR) problem has been resolved, and credible, valuable posters have been reinstated. I've already cancelled my premium membership some time ago. I suggest you do the same. With kind regards to all Trading Cyclist (aka TC)
53 comments
Read more

June 6, 2017. Buy Out at 63?

Take a spin on our BO pricing model! The Trading Cyclist Our model is generating a range of $35-63 BO PPS , per the low/high case scenarios below - where only the Voc  price  is different (25 k vs 50k). My hunch is that this is both conservative and in the ballpark.  It's conservative b/c: 1) patient population is consistent with Aurinia's projection; 2) assumes only 35% of population on treatment; 3) assumes 75% discount for European market; 4) pricing is at 50% of range projected by Aurinia; 5) uses target P/S ratio of 3, which is below Biotech industry average of 5.0.  Outcome   Patient Pool  (Same for both Scenarios)  Pricing :  Price/Sales ratio   Here's the  Link to the model Low end BO PPS w/30% discount:  $35  ($50 no discount)  High End BO PPS w/30% discount  $63  ($90 no discount)  Prev: 26.5 per 100,000 (Based on epidemiological study)  Total Patient po...
25 comments
Read more